You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

96 Items
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Curative
May 2019
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit
    prednisone
ODB - General Benefit
    chlorambucil
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL), Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
ODB - General Benefit
    prednisone
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Previously Untreated Chronic Lymphocytic Leukemia
ODB - General Benefit
    chlorambucil
Nov 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Dec 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
ODB - General Benefit
    chlorambucil
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
Oct 2018
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
May 2019
Cancer Type: Head and Neck     
Intent: Neoadjuvant
Feb 2017
Cancer Type: Gastrointestinal, Anus     
Intent: Palliative
Jun 2019
Cancer Type: Head and Neck     
Intent: Palliative
May 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Adjuvant, Palliative
Updated
Nov 2019